clinical trial · NCT06682169
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase3·recruiting·n = 182
Graft-versus-host DiseaseRovadicitinibImatinibMethotrexateMycophenolate mofetilRituximab
brief summary
The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can significantly improve the objective response rate of subjects at week 24.
started
Nov 20, 2024
primary completion
Oct 1, 2029
completion
Dec 1, 2030
last updated
Dec 8, 2025
official title
A Randomized, Open Label, Positive Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of the Selected Regimen of Rovadicitinib in Moderate to Severe Chronic Graft-versus-host Disease in Third Line and Beyond
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol